$ALNY News Leading stocks prove their mettle 11:53 a.m.

New Post Public Reply Private Reply Replies (0) Message Board

Dec 16, 2013 at 10:11 AM

$ALNY News

Leading stocks prove their mettle 11:53 a.m. Aug. 22, 2013 - The Trading Deck
Don't fight the tape 10:27 a.m. May 28, 2013 - The Trading Deck
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Synageva director bought shares for trust 1:41 p.m. Jan. 17, 2013 - Insider Monkey
Six stocks to watch for potential up moves 11:14 a.m. Jan. 17, 2013 - The Trading Deck
S&P 500 challenges the 1,440 resistance 9:27 a.m. Sept. 13, 2012 - Michael Ashbaugh
Investing in ‘junk DNA’ 9:28 p.m. Sept. 11, 2012 - Jen Wieczner
Monsanto inks biopesticides deal with Alnylam 8:30 a.m. Aug. 28, 2012 - MarketWatch.com
12 biotech stocks hit 52-week highs 2:43 p.m. July 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 2:35 p.m. July 16, 2012 - MarketWatch
Alnylam soars 31% on drug study 10:19 a.m. July 16, 2012 - Val Brickates Kennedy
Alnylam: Progress with genetic-disorder treatment 6:35 a.m. July 16, 2012 - MarketWatch.com
3 med stocks to get your heart pumping 12:53 p.m. April 5, 2012 - The Trading Deck
Stocks to watch Thursday: GM, Agilent, NetApp 6:51 a.m. Feb. 16, 2012 - MarketWatch
Alnylam climbs 16% on stock offer pricing 2:07 p.m. Feb. 15, 2012 - Val Brickates Kennedy
Stocks to watch Wednesday: Hartford, Aflac, Zynga 6:45 a.m. Feb. 15, 2012 - MarketWatch
Tuesday’s biggest gaining and declining stocks 5:47 p.m. Feb. 14, 2012 - Sue Chang
MGM, Monsanto among Tuesday upgrades 10:54 a.m. Sept. 13, 2011 - Tom Bemis
Vertex, Alnylam gain in drug-stock trading 12:22 p.m. Feb. 23, 2011 - Val Brickates Kennedy
Alnylam shares jump on analyst upgrade 9:55 a.m. Feb. 23, 2011 - Val Brickates Kennedy

Alnylam: Bold Moves Toward A New Class Of Medicine 6:33 p.m. Dec. 11, 2013 - Seeking Alpha
Isis Ally Alnylam - Trying To Understand Its Astounding Valuations 10:06 a.m. Dec. 10, 2013 - Seeking Alpha
Alnylam Presents New Pre-clinical Data on ALN-AT3 for Treatment of Hemophilia and RBD at ASH 7:59 p.m. Dec. 9, 2013 - benzinga.com
Alnylam's CEO Presents at The 25th Annual Piper Jaffray Healthcare Conference (Transcript) 4:21 p.m. Dec. 4, 2013 - Seeking Alpha
Best Biotech CEO of 2013: Your Vote Counts 8:07 a.m. Dec. 4, 2013 - TheStreet.com
Alnylam Pharmaceuticals' Management Presents at Deutsche Bank BioFEST Conference (Transcript) 2:01 p.m. Dec. 2, 2013 - Seeking Alpha
Alnylam Earns Milestone Payment - Analyst Blog 5:52 p.m. Nov. 26, 2013 - Zacks.com
Today's Stocks Driving Success For The Drugs Industry 12:04 p.m. Nov. 26, 2013 - TheStreet.com
Alnylam Earns $7M Milestone Payment from Partner Genzyme for Phase II Success with Patisiran 6:02 a.m. Nov. 25, 2013 - benzinga.com
Biotech Stock Roundup: Vanda Soars, Sarepta Slumps - Analyst Blog 11:33 a.m. Nov. 20, 2013 - Zacks.com
First Week Of ALNY January 2014 Options Trading 11:55 a.m. Nov. 19, 2013 - TheStreet.com
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics at American Heart Association Meeting 3:54 p.m. Nov. 17, 2013 - benzinga.com
Alnylam Pharmaceuticals Larger Than S&P 500 Component Teradyne 4:39 p.m. Nov. 15, 2013 - TheStreet.com
Alnylam Announces Positive Phase II Data for Patisiranfor for Treatment of TTR-Mediated Amyloidosis, Initiates Phase III Trial 8:26 a.m. Nov. 10, 2013 - benzinga.com
Wider-than-Expected Q3 Loss at Alnylam - Analyst Blog 10:00 a.m. Nov. 7, 2013 - Zacks.com
10-Q: ALNYLAM PHARMACEUTICALS, INC. 8:20 a.m. Nov. 7, 2013 - Edgar Online - (EDG = 10Q, 10K)
Alnylam Pharmaceuticals' CEO Discusses Q3 2013 Results - Earnings Call Transcript 11:43 p.m. Nov. 6, 2013 - Seeking Alpha
3 Potential Game-Changers In The Biotech Industry 4:45 p.m. Nov. 5, 2013 - Seeking Alpha
Alnylam Presents New Pre-clinical Data on ALN-AAT 3:12 p.m. Nov. 2, 2013 - benzinga.com
Pipeline Progress at Alnylam - Analyst Blog 6:05 p.m. Oct. 30, 2013 - Zacks.com

Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR) 8:00 a.m. Today - BusinessWire
Dividends, FDA Approved Treatments, Clinical Data Presentations and Completed License Applications - Research Report on Medtronic, Auxilium, Alnylam, Infinity, and Halozyme 8:00 a.m. Dec. 11, 2013 - PR Newswire
Alnylam Presents New Pre-clinical Data on ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD) 7:00 p.m. Dec. 9, 2013 - BusinessWire
New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases, Demonstrate up to 98% Serum C5 Knockdown and up to 94% Inhibition of Hemolytic Activity in Non-Human Primates 7:30 p.m. Dec. 8, 2013 - BusinessWire
Healthcare Sector Announce Awards, Conference Participation, Partnerships, and Closure of Public Offering - Research Report on Regeneron, Alnylam, Galena Biopharma, Amedisys, and Aeterna Zentaris 8:00 a.m. Dec. 3, 2013 - PR Newswire
Alnylam to Webcast Presentation at Upcoming Investor Conferences 4:00 p.m. Nov. 25, 2013 - BusinessWire
Upcoming Webinars, FDA Clearances, Preclinical Data Presentations, Completed Acquisitions and Financial Results - Research Report on Teva, Boston Scientific, Alnylam, Wright Medical, and Onconova 8:00 a.m. Nov. 25, 2013 - PR Newswire
Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) 7:00 a.m. Nov. 25, 2013 - BusinessWire
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for Cardiovascular Disease at American Heart Association Meeting 4:00 p.m. Nov. 17, 2013 - BusinessWire
Healthcare Sector Announced Financial Results and Recognition - Research Report on Alnylam Pharmaceuticals, Opko, Enzymotec, Cambrex, and XOMA 8:00 a.m. Nov. 15, 2013 - PR Newswire
RXi Pharmaceuticals' Valuation Moves From Product To Platform 10:19 a.m. Nov. 12, 2013 - ACCESSWIRE
Alnylam Receives Fast Track Designation for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) 7:00 a.m. Nov. 11, 2013 - BusinessWire
Tekmira's Partner Initiates Phase III Trial With LNP-Enabled Patisiran (ALN-TTR02) 11:28 p.m. Nov. 10, 2013 - GlobeNewswire
Clinical Trial Initiations, Conferences Participations, Strategic Collaborations, and Presentation of New Pre-Clinical Data - Research Report on Biogen Idec, BioMarin, Medivation, Cytori, and Alnylam 8:00 a.m. Nov. 8, 2013 - PR Newswire
Alnylam to Present New Pre-clinical Data on Multiple RNAi Therapeutic Programs at 55th Annual Meeting of the American Society of Hematology (ASH) 9:00 a.m. Nov. 7, 2013 - BusinessWire
Alnylam Pharmaceuticals Reports Third Quarter 2013 Financial Results 4:00 p.m. Nov. 6, 2013 - BusinessWire
Alnylam Presents New Pre-clinical Data on ALN-AAT, an RNAi Therapeutic Targeting Alpha-1-Antitrypsin (AAT) for the Treatment of AAT Deficiency Liver Disease 2:00 p.m. Nov. 2, 2013 - BusinessWire
Acquisitions, Financial Results, Clinical Trial Applications, and Upcoming Earnings Schedules - Research Report on Illumina, DENTSPLY, Alnylam, Sirona, and Santarus 9:00 a.m. Nov. 1, 2013 - PR Newswire
Alnylam to Webcast Conference Call Discussing Third Quarter 2013 Financial Results 4:00 p.m. Oct. 30, 2013 - BusinessWire
Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia A and B 8:00 a.m. Oct. 29, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

CVS Study: GLP-1 Drugs Effective But Costly

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...